The Clorox Company $CLX Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its stake in The Clorox Company (NYSE:CLX) by 30.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,463 shares of the company’s stock after selling 35,039 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.07% of Clorox worth $9,661,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Clorox during the 2nd quarter worth approximately $190,429,000. Hsbc Holdings PLC raised its stake in shares of Clorox by 118.8% during the first quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after purchasing an additional 589,544 shares during the last quarter. Nuance Investments LLC lifted its holdings in shares of Clorox by 182.5% during the second quarter. Nuance Investments LLC now owns 848,106 shares of the company’s stock worth $101,832,000 after purchasing an additional 547,839 shares during the period. Robeco Institutional Asset Management B.V. grew its position in Clorox by 101.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock valued at $130,123,000 after buying an additional 546,761 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Clorox by 412.1% in the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock valued at $88,167,000 after buying an additional 481,846 shares during the period. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Stock Down 0.4%

Shares of NYSE CLX opened at $107.32 on Friday. The firm’s 50-day moving average is $113.61 and its two-hundred day moving average is $121.26. The company has a market capitalization of $13.09 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The Clorox Company has a 12-month low of $98.20 and a 12-month high of $171.37. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.07. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the previous year, the firm posted $1.86 EPS. The company’s quarterly revenue was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Equities analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Wednesday, January 28th. Clorox’s dividend payout ratio is currently 77.86%.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Bank of America reduced their target price on shares of Clorox from $135.00 to $125.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Citigroup cut their price target on shares of Clorox from $130.00 to $120.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. UBS Group set a $119.00 price objective on Clorox and gave the company a “neutral” rating in a report on Tuesday, November 4th. Morgan Stanley cut their target price on Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Finally, Wells Fargo & Company reduced their price target on Clorox from $125.00 to $117.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. One research analyst has rated the stock with a Buy rating, thirteen have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $125.69.

Insiders Place Their Bets

In other news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction on Friday, November 21st. The shares were bought at an average cost of $104.13 per share, for a total transaction of $416,520.00. Following the acquisition, the director owned 13,000 shares in the company, valued at approximately $1,353,690. This trade represents a 44.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.63% of the stock is owned by company insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.